Last reviewed · How we verify

Reopro — Competitive Intelligence Brief

Reopro (ABCIXIMAB) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Integrin alpha-IIb/beta-3 Cardiovascular Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Reopro (ABCIXIMAB) — Johnson & Johnson.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Reopro TARGET ABCIXIMAB Johnson & Johnson marketed Integrin alpha-IIb/beta-3 1993-01-01
Aggrastat TIROFIBAN Medicure marketed Platelet Aggregation Inhibitor Integrin alpha-IIb/beta-3 1998-01-01
Integrilin EPTIFIBATIDE Merck & Co. marketed Platelet Aggregation Inhibitor [EPC] Integrin alpha-IIb/beta-3 1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Reopro — Competitive Intelligence Brief. https://druglandscape.com/ci/abciximab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: